Lunai Bioworks achieves complete regression of both primary and metastatic pancreatic tumors in preclinical humanized models, marking a breakthrough in allogeneic cancer immunotherapy
Lunai Bioworks Announces Publication of Second-Generation Allogeneic Dendritic Cell Therapy Platform in the journal "Vaccines". LOS ANGELES, Nov. 6, 2025 /PRNewswire/ -- Lunai Bioworks (NASDAQ: LNAI), an AI-powered drug discovery and biodefense...
MicroCloud Hologram Inc. announces optimization of stacked sparse autoencoders through DeepSeek model
SHENZHEN, China, Feb. 14, 2025 /PRNewswire/ -- MicroCloud Hologram Inc. (NASDAQ: HOLO), ("HOLO" or the "Company"), a technology service provider, they Announced the deep optimization of stacked sparse autoencoders through the DeepSeek open-source...